Alector

Edit info

Founded: 2013

Location: South SF, CA

Employee range: 101-250

Clinical stage: Clin3

Therapy area: Frontotemporal dementia

Drug types: NEU

Lead product: AL001 (partner: GSK)

Funding: 100-500M

alector.com

linkedin.com

job board

Drug notes:

Also Clin2 Alzheimer's; AL002 Clin2 Alzheimer's (partner: AbbVie)

About:

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.